Dawson James Securities Recent News
UPDATE: Dawson James Securities Initiates Coverage on Onyx Pharmaceuticals with Market Outperform Rating, $91 PT
Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals
UPDATE: Dawson James Securities Downgrades SeraCare Life Sciences to Neutral
Dawson James Securities: NeuroMetrix Launches New Product
Dawson James Securities: Level 3 Movin' On Up as Losses Narrow
Dawson James Securities: Ultra Petroleum Reported Mixed 4Q11 Results